Ozempic for Heart Disease — The New Research
Julia Cartwright explores groundbreaking research showing semaglutide (Ozempic/Wegovy) reduces heart failure hospitalizations by 70% in HFpEF patients—a stubborn condition affecting millions with few treatment options. The episode examines clinical trial data revealing benefits beyond weight loss, including reduced inflammation and improved heart function, marking a potential paradigm shift in cardiovascular medicine. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.
4 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der Ozempic for Heart Disease — The New Research-Community!